Novel approaches to study immune responses to post translational modifications for cancer detection
研究癌症检测翻译后修饰免疫反应的新方法
基本信息
- 批准号:10463894
- 负责人:
- 金额:$ 18.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-21 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AntibodiesAntibody ResponseAutoantibodiesB-LymphocytesBiochemical MarkersBiological MarkersBiometryBiopsyBlindedBreastBreast Cancer Early DetectionCLIA certifiedCancer ControlCancer DetectionCancer PatientCellsDataDetectionDevelopmentDevicesDiagnosisDiseaseEarly Detection Research NetworkEarly DiagnosisEnzyme-Linked Immunosorbent AssayEpitopesExtracellular DomainGALNT3 geneGlycoproteinsGoalsHumanHuman PapillomavirusImageImaging technologyImmuneImmune SeraImmune responseImmunityIn SituLaboratoriesLengthMalignant NeoplasmsMalignant neoplasm of lungMammographyMeasuresMedical OncologyMembrane ProteinsMethodsMolecular ChaperonesMorbidity - disease rateMucinsOvarianPatientsPerformancePhasePolysaccharidesPost-Translational Protein ProcessingPredictive ValueProductionProtein GlycosylationProteinsProteomeProteomicsProtocols documentationRecombinantsReproducibilityResearch DesignRibosomesScreening for cancerScreening procedureSensitivity and SpecificitySerumStructureSuggestionSurfaceTechnologyTestingTrainingTranslatingTumor AntigensValidationbasebiomarker developmentbiomarker discoverybiomarker identificationbiomarker signaturecancer biomarkerschest computed tomographyclinical biomarkerscostdesignearly detection biomarkersgene cloningglycoproteomicsglycosylationglycosyltransferaseimmunogenicimprovedimproved outcomemalignant breast neoplasmmortalitynovelnovel strategiesoverexpressionpolypeptidepotential biomarkerpreventprogramsprotein expressionquality assurancerapid detectionrapid techniquescreeningsealstructural glycoproteinsugarsugar nucleotidesynthetic peptidetooltriple-negative invasive breast carcinomatumorvalidation studies
项目摘要
Project Summary/Abstract
Despite advances in screening and treatment, mortalities from breast and lung cancers have remained high in
the US over the last 20 years. It is widely accepted that early detection is critical to improving outcomes in both
diseases. Both also rely on imaging for screening, but false positive and false negative detection are
associated with unnecessary biopsies, missed diagnoses, and costs. There is an urgent need for biochemical
markers that improve the performance of imaging technologies. Our laboratories have been successful at
identifying useful cancer biomarkers by exploiting patients’ own ability to produce antibodies against tumor-
associated antigens (TAA), referred to as tumor-associated autoantibodies (TAAb). With prior EDRN support,
we developed high-throughput programmable protein display methods for the rapid detection and validation of
autoantibody biomarker signatures in breast and lung cancers. Our breast cancer TAAb biomarkers have been
licensed and integrated into Videssa™ Breast that is now available as CLIA-certified test. Our triple negative
breast cancer markers have been validated in blinded phase 2 multicenter validation studies. These
demonstrate the great utility of TAAb in cancer early detection. However, the sensitivities of most TAAbs is
moderate and there is a suggestion that greater sensitivity and specificity could be obtained by examining
TAAb directed at aberrantly modified proteins in cancers. Our central hypothesis is that aberrant protein
glycosylation, a hallmark of breast and lung cancers, induces glycoprotein-specific TAAb that can be measured
as specific serum biomarkers of these cancers. Alterations in glycosylation are highly immunogenic, and there
is strong historical evidence for significant antibody responses to cancer-altered glycoproteins. However, all
current protein (or polypeptide) display tools allow limited or no post-translational modification. This historical
roadblock has prevented the identification of these biomarkers because of the lack of screening methods that
test immunogenic structural glycoproteins. We introduce a tool for the high-throughput display of full-length
proteins decorated with cancer-specific O-glycan structures. This will revolutionize the opportunity to screen
glycan-protein epitopes in their natural context. Our team comprises strong expertise in functional proteomics,
biomarker development, glycoproteomics, medical oncology and biostatistics. Targeted proteins will include:
the extra-cellular domains of relevant single pass membrane proteins, proteins known to be O-glycosylated
and overexpressed in the two cancers, and all known mucins. They will be translated in situ using human
ribosomes and chaperone proteins and then systematically decorated with Tn and STn O-GalNAc-type glycans
by consecutive addition of recombinant glycosyltransferases and sugar nucleotides to mirror what occurs in the
two cancers. Adhering to the principles of PRoBE design, we will screen these arrays with cancer patient and
control sera. Our study will focus on cancer patients and non-cancer subjects with positive imaging findings.
Study design will include Phase I discovery (arrays/ELISA) and Phase II validation using ELISA.
项目概要/摘要
尽管筛查和治疗取得了进步,但乳腺癌和肺癌的死亡率仍然很高
美国过去20年。人们普遍认为,早期检测对于改善两种疾病的结果至关重要
疾病。两者也都依赖成像进行筛查,但假阳性和假阴性检测
与不必要的活检、漏诊和费用相关。迫切需要生化
提高成像技术性能的标记。我们的实验室已成功
通过利用患者自身产生抗肿瘤抗体的能力来识别有用的癌症生物标志物
相关抗原(TAA),称为肿瘤相关自身抗体(TAAb)。凭借先前的 EDRN 支持,
我们开发了高通量可编程蛋白质展示方法,用于快速检测和验证
乳腺癌和肺癌中的自身抗体生物标志物特征。我们的乳腺癌 TAAb 生物标志物已
获得许可并集成到 Videssa™ Breast 中,现已作为 CLIA 认证的测试提供。我们的三重阴性
乳腺癌标志物已在盲法 2 期多中心验证研究中得到验证。这些
证明 TAAb 在癌症早期检测中的巨大效用。然而,大多数 TAAb 的敏感性是
中等,有人建议通过检查可以获得更高的敏感性和特异性
TAAb 针对癌症中异常修饰的蛋白质。我们的中心假设是异常蛋白质
糖基化是乳腺癌和肺癌的标志,可诱导可测量的糖蛋白特异性 TAAb
作为这些癌症的特异性血清生物标志物。糖基化的改变具有高度免疫原性,并且
这是抗体对癌症改变的糖蛋白产生显着反应的有力历史证据。然而,所有
目前的蛋白质(或多肽)展示工具允许有限的或不允许翻译后修饰。这座历史悠久的
由于缺乏筛选方法,阻碍了这些生物标志物的识别。
测试免疫原性结构糖蛋白。我们介绍了一种用于全长高通量显示的工具
用癌症特异性 O-聚糖结构装饰的蛋白质。这将彻底改变筛选机会
天然环境中的聚糖蛋白表位。我们的团队拥有功能蛋白质组学方面深厚的专业知识,
生物标志物开发、糖蛋白组学、医学肿瘤学和生物统计学。目标蛋白质将包括:
相关单程膜蛋白的胞外结构域,已知为 O-糖基化的蛋白
并在两种癌症和所有已知的粘蛋白中过度表达。它们将使用人工进行现场翻译
核糖体和伴侣蛋白,然后用 Tn 和 STn O-GalNAc 型聚糖系统地修饰
通过连续添加重组糖基转移酶和糖核苷酸来反映在
两种癌症。秉承 PRoBE 设计原则,我们将用癌症患者和患者来筛选这些阵列。
对照血清。我们的研究将重点关注具有阳性影像学结果的癌症患者和非癌症受试者。
研究设计将包括第一阶段发现(阵列/ELISA)和使用 ELISA 的第二阶段验证。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Programmable protein arrays for immunoprofiling HPV-associated cancers.
- DOI:10.1002/pmic.201500376
- 发表时间:2016-04
- 期刊:
- 影响因子:3.4
- 作者:Ewaisha R;Meshay I;Resnik J;Katchman BA;Anderson KS
- 通讯作者:Anderson KS
Serum autoantibodyome reveals that healthy individuals share common autoantibodies.
- DOI:10.1016/j.celrep.2022.110873
- 发表时间:2022-05-31
- 期刊:
- 影响因子:8.8
- 作者:Shome, Mahasish;Chung, Yunro;Chavan, Ramani;Park, Jin G.;Qiu, Ji;LaBaer, Joshua
- 通讯作者:LaBaer, Joshua
Proteomic Monitoring of B Cell Immunity.
B 细胞免疫的蛋白质组学监测。
- DOI:10.1007/978-1-4939-3387-7_6
- 发表时间:2016
- 期刊:
- 影响因子:0
- 作者:Ewaisha,Radwa;Anderson,KarenS
- 通讯作者:Anderson,KarenS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karen Sue Anderson其他文献
Karen Sue Anderson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karen Sue Anderson', 18)}}的其他基金
Southwest EDRN Clinical Validation Center for Head and Neck Cancer
西南头颈癌EDRN临床验证中心
- 批准号:
10706931 - 财政年份:2023
- 资助金额:
$ 18.32万 - 项目类别:
High-throughput immunoproteomics for cancer biomarker discovery
用于癌症生物标志物发现的高通量免疫蛋白质组学
- 批准号:
10688268 - 财政年份:2022
- 资助金额:
$ 18.32万 - 项目类别:
Rapid Point of Care Detection of HPV-Associated Malignancies
HPV 相关恶性肿瘤的快速护理点检测
- 批准号:
10006505 - 财政年份:2017
- 资助金额:
$ 18.32万 - 项目类别:
Rapid Point of Care Detection of HPV-Associated Malignancies
HPV 相关恶性肿瘤的快速护理点检测
- 批准号:
10246794 - 财政年份:2017
- 资助金额:
$ 18.32万 - 项目类别:
Rapid Point of Care Detection of HPV-Associated Malignancies
HPV 相关恶性肿瘤的快速护理点检测
- 批准号:
9221542 - 财政年份:2017
- 资助金额:
$ 18.32万 - 项目类别:
Rapid Point of Care Detection of HPV-Associated Malignancies
HPV 相关恶性肿瘤的快速护理点检测
- 批准号:
9933545 - 财政年份:2017
- 资助金额:
$ 18.32万 - 项目类别:
Rapid Point of Care Detection of HPV-Associated Malignancies
HPV 相关恶性肿瘤的快速护理点检测
- 批准号:
10471927 - 财政年份:2017
- 资助金额:
$ 18.32万 - 项目类别:
Novel approaches to study immune responses to post translational modifications for cancer detection
研究癌症检测翻译后修饰免疫反应的新方法
- 批准号:
9355593 - 财政年份:2016
- 资助金额:
$ 18.32万 - 项目类别:
相似海外基金
Characterizing the SARS-CoV-2 antibody response and associations with patient factors: Serological profiling of participants enrolled in the GENCOV study
描述 SARS-CoV-2 抗体反应及其与患者因素的关联:参与 GENCOV 研究的参与者的血清学分析
- 批准号:
495256 - 财政年份:2023
- 资助金额:
$ 18.32万 - 项目类别:
Understanding the human antibody response to a malaria transmission-blocking vaccine
了解人类抗体对疟疾传播阻断疫苗的反应
- 批准号:
MR/X009491/1 - 财政年份:2023
- 资助金额:
$ 18.32万 - 项目类别:
Research Grant
Probing the role of peptidoglycan modification in the antibody response to Staphylococcus aureus
探讨肽聚糖修饰在金黄色葡萄球菌抗体反应中的作用
- 批准号:
10549646 - 财政年份:2023
- 资助金额:
$ 18.32万 - 项目类别:
Identification of the antigenic targets of the clonal antibody response to Clostridioides difficile infection
鉴定针对艰难梭菌感染的克隆抗体反应的抗原靶点
- 批准号:
10742376 - 财政年份:2023
- 资助金额:
$ 18.32万 - 项目类别:
Genetic, structural and functional profiling of the human antibody response to arenavirus infection
人类抗体对沙粒病毒感染反应的遗传、结构和功能分析
- 批准号:
10688292 - 财政年份:2022
- 资助金额:
$ 18.32万 - 项目类别:
Molecular dissection of IgA antibody response by developing monoclonal IgA antibodies from nasal mucosa of mice
通过从小鼠鼻粘膜中开发单克隆 IgA 抗体对 IgA 抗体反应进行分子剖析
- 批准号:
22H02875 - 财政年份:2022
- 资助金额:
$ 18.32万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mapping the antibody response to Trypanosoma brucei variant surface glycoprotein
绘制布氏锥虫变异表面糖蛋白的抗体反应
- 批准号:
10634694 - 财政年份:2022
- 资助金额:
$ 18.32万 - 项目类别:
Genetic, structural and functional profiling of the human antibody response to arenavirus infection
人类抗体对沙粒病毒感染反应的遗传、结构和功能分析
- 批准号:
10514498 - 财政年份:2022
- 资助金额:
$ 18.32万 - 项目类别:
Mapping the antibody response to Trypanosoma brucei variant surface glycoprotein
绘制布氏锥虫变异表面糖蛋白的抗体反应
- 批准号:
10527979 - 财政年份:2022
- 资助金额:
$ 18.32万 - 项目类别:
Factors related to antibody response of COVID-19 vaccines: with focusing on metabolomics
与 COVID-19 疫苗抗体反应相关的因素:重点关注代谢组学
- 批准号:
22H03334 - 财政年份:2022
- 资助金额:
$ 18.32万 - 项目类别:
Grant-in-Aid for Scientific Research (B)














{{item.name}}会员




